

MicroRNA-21 Inhibits the Apoptosis of Osteosarcoma Cell Line SAOS-2 via Targeting Caspase 8

Bin Xu, Hehuan Xia, Junming Cao, Zhihong Wang, Yipeng Yang, and Yongsheng Lin

Department of Orthopedics, The Third Hospital of Hebei Medical University, Shijiazhuang, P.R. China

Currently, multiple microRNAs (miRNAs) have been found to play vital roles in the pathogenesis of osteosarcoma. This study aimed to investigate the role of miR-21 in osteosarcoma. The level of miR-21 in 20 pairs of osteosarcoma and corresponding adjacent tissues was monitored by qPCR. Human osteosarcoma cell line SAOS-2 was transfected with either miR-21 mimic or miR-21 inhibitor, and then cell viability, survival, and apoptosis were measured by MTT, colony formation assay, and flow cytometry. A target of miR-21 was predicted by the microRNA.org database and verified in vitro by using luciferase reporter, qPCR, and Western blot analyses. Finally, cells were cotransfected with siRNA against caspase 8 and miR-21 inhibitor, and the apoptotic cell rate was determined again. Results showed that the mRNA level of miR-21 was highly expressed in osteosarcoma tissues compared with adjacent tissues. Overexpression of miR-21 improved cell viability and survival but suppressed apoptosis. Caspase 8 was a direct target of miR-21, and it was negatively regulated by miR-21. Moreover, miR-21 suppression attenuated caspase 8 silencing and induced the decrease in apoptosis. In conclusion, overexpression of miR-21 suppressed SAOS-2 cell apoptosis via directly targeting caspase 8.

Key words: MicroRNA-21; Osteosarcoma; Cell survival; Apoptosis; Caspase 8

INTRODUCTION

Osteosarcoma is a cancerous tumor of the bone characterized by the direct formation of immature bone or osteoid tissue by the tumor cells¹. To date, the pathogenesis of osteosarcoma remains unclear, although the retinoblastoma gene, bone dysplasias, Li-Fraumeni syndrome, and Rothmund-Thomson syndrome have been identified as high risks for osteosarcoma²⁻⁴. Currently, surgical resection therapy and chemotherapy have been practiced in patients with osteosarcoma⁵. However, the outcome for those patients with metastatic or recurrent osteosarcoma remains dismally poor⁶. Therefore, a better understanding of the tumorigenesis and progression of osteosarcoma could lead to the development of novel therapeutic approaches for this tumor.

MicroRNAs (miRNAs) are a category of short, non-coding, single-stranded RNAs of about 22 nucleotides that are widely found in both animals and plants⁷. miRNAs regulate their targets by inhibiting their translation and/or by promoting degradation of their mRNA⁸. Currently, several miRNAs, such as miR-367, miR-224, and miR-184, have been suggested as candidates in the treatment of osteosarcoma by targeting their specific mRNAs⁹⁻¹¹.

The expression of miR-21 is remarkably increased in a number of tumors, such as breast, colon, gastric, and pancreatic cancers¹². In osteosarcoma, miR-21 is highly expressed, and overexpression of miR-21 promotes proliferation and invasion and suppresses apoptosis in the human osteosarcoma line MG63¹³. Furthermore, miR-21 is capable of sensitizing human osteosarcoma cells to cisplatin, implying that miR-21 is implicated in the modulation of drug-induced resistance¹⁴. However, the detailed function of miR-21 in osteosarcoma and its underlying molecular mechanism remain elusive.

Therefore, this study aimed to investigate the impact of miR-21 on osteosarcoma cell apoptosis and its potential mechanism. The expression of miR-21 in osteosarcoma tissue and adjacent tissue samples was monitored. Human osteosarcoma cell line SAOS-2 was used and transfected with miR-21 mimic, miR-21 inhibitor, or control to assess the effects of miR-21 on cell survival and apoptosis. A target of miR-21 was predicted and verified in vitro, revealing a possible molecular mechanism of miR-21 in osteosarcoma. Our study showed the potential role of miR-21 in osteosarcoma and might provide possibilities for its use in treating this disease.

MATERIALS AND METHODS

Human Tissue Samples and Cell Culture

Human osteosarcoma tissue and paired normal adjacent tissue samples were obtained during standard surgery from 20 osteosarcoma patients (12 men and 8 women; aged 19 to 46 years). These patients were admitted to the hospital between July 2012 and January 2015. None of the patients had received blood transfusion, radiotherapy, or chemotherapy before surgery. All tissues were frozen immediately in liquid nitrogen at the time of surgery and stored at -80°C for RNA extraction¹⁵. The study was approved by our local ethics committee, and written informed consent was obtained from all subjects for the use of their osteosarcoma and adjacent tissues for research.

Human osteosarcoma cell line SAOS-2 was obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco), 100 U/ml penicillin, and 100 U/ml streptomycin (Sigma-Aldrich, St. Louis, MO, USA)¹⁶. Cells were incubated in a humidified 5% CO_2 incubator at 37°C .

RNA Extraction and Real-Time Quantitative PCR (qPCR)

Total RNA was extracted by TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). For cDNA synthesis, 2 μg of total RNA was reverse transcribed using Transcriptor First-Strand cDNA Synthesis Kit (Roche, USA) according to the manufacturer's instructions. The real-time qPCR was performed using FastSTART Universal SYBR Green Master (ROX) (Roche) on the ABI PRISM 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA)¹⁵. Data were analyzed using the $2^{-\Delta\Delta\text{CT}}$ method. Levels of caspase 8 and miR-21 were normalized to those of GAPDH and U6, respectively. All primers were synthesized by GenePharma (Shanghai, P.R. China).

Cell Transfection

Cells were plated on 60-mm dishes and cultured for 24 h. Subsequently, miR-21 mimic, miR-21 inhibitor, or control, and/or small interfering RNA (siRNA) against caspase 8 (GenePharma) were transfected into cells. The transfection was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions¹⁷. After 48 h, cells were collected for use in subsequent experiments.

Cell Viability Assay

Cell viability was measured by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay.

After cells were transfected with miR-21 mimic, miR-21 inhibitor, or control, cells were planted into 96-well plates at a density of 2×10^3 cells/well and cultured for 1–4 days. Afterward, 20 μl of MTT (5 mg/ml; Sigma-Aldrich) was added into each well and incubated for another 4 h at 37°C . Then 150 μl of dimethyl sulfoxide (DMSO; Sigma-Aldrich) was added, and the plates were shaken for 10 min. The absorbance was detected under a Multiskan EX (Thermo, Finland) at 450 nm¹⁸.

Colony Formation Assay

After cells were transfected with miR-21 mimic, miR-21 inhibitor, or control, cells were seeded onto the cultured dishes (6 cm in diameter) at a density of 1×10^3 cells/well. Then the cells were incubated for 14 days at 37°C . Colonies were stained with Giemsa (Sigma-Aldrich) for 30 min, and colony numbers were counted under an optical microscope (Leica Microsystems, Wetzlar, Germany)¹⁹.

Apoptosis Assay

Cell apoptosis was assessed using the Annexin-V/FITC and PI apoptosis detection Kit (Becton Dickinson, Franklin Lakes, NJ, USA). Briefly, 48 h after transfection, cells were collected and resuspended in 500 μl of annexin-binding buffer. After 30 min of incubation, 10 μl of annexin V-FITC and 5 μl of PI were added and the samples were incubated for another 30 min in the dark at room temperature. Apoptotic cells were immediately analyzed by flow cytometry (Becton Dickinson)²⁰.

Luciferase Reporter Assay

The 3'-UTR of caspase 8 was amplified by PCR and placed in the pmir-Report vector (Ambion, Grand Island, NY, USA). These vectors were cotransfected with miR-21 mimic, miR-21 inhibitor, or control into cells using Lipofectamine 2000 (Invitrogen). After 48 h, luciferase assay was carried out using the dual-luciferase reporter assay system (Promega, Madison, WI, USA) as previously described²¹.

Western Blot

Cellular protein in the transfected cells was extracted by RIPA lysis buffer (Beyotime, Shanghai, P.R. China). Protein samples were separated on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride membranes. The membranes were then blocked with 5% skim milk for 1 h at room temperature and were incubated with the special primary antibodies: caspase 8 (1C12), cleaved caspase 8 p18 (Asp387), or GAPDH (D4C6R) (all at a dilution of 1:1,000; Cell Signaling Technology, Beverly, MA, USA) at 4°C overnight. The membranes were




Figure 2. Overexpression of miR-21 increased SAOS-2 cell survival while suppressing apoptosis. miR-21 mimic, miR-21 inhibitor, or control was transfected into SAOS-2 cells. Subsequently, (A) the transfection efficiency was tested by qPCR, (B) cell viability was determined by MTT assay, (C) cell survival was measured by colony formation assay, and (D, E) the apoptotic cell rate was detected by flow cytometry. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ when compared to the control.




A**B****C**

Figure 3. Caspase 8 was a target gene of miR-21. (A) The target of miR-21 was predicted using the microRNA.org database. (B) miR-21 mimic or (C) miR-21 inhibitor was cotransfected with the pmiR-Report vector containing full-length caspase 8 3'-UTR or a mutated seed site within pmiR-caspase 8 into SAOS-2 cells, and dual-luciferase reporter assay was then performed. NS, no significance. $^{**}p < 0.01$, $^{***}p < 0.001$ when compared to the control.

DISCUSSION

Currently, plenty of miRNAs have been found to serve as oncogenes or antioncogenes in osteosarcoma⁹⁻¹¹. However, little is known about the potential role of miR-21 in the pathogenesis of osteosarcoma. In the current study, we found that the expression of miR-21 was notably elevated in osteosarcoma tissues. Overexpression of miR-21 significantly increased cell survival while suppressing apoptosis in SAOS-2 cells. Moreover, caspase 8 was verified as a target gene of miR-21, and in vitro investigations suggested that it was negatively regulated by miR-21. Of note, suppression of miR-21 attenuated caspase 8-silencing-induced decrease in apoptosis, implying that miR-21 inhibited SAOS-2 cell apoptosis via targeting caspase 8.

An increasing number of studies have demonstrated that miRNAs could modulate osteosarcoma cell apoptosis. Kawano et al. demonstrated that miR-93 decreased apoptosis in osteosarcoma cells²². Lin et al. found that miR-184 overexpression reduced doxorubicin-induced cell apoptosis in osteosarcoma cells¹¹. In the current study, our findings suggested that miR-21 was upregulated in osteosarcoma tissues, and overexpression of miR-21 notably increased cell survival while suppressing apoptosis in the osteosarcoma cell line SAOS-2. Analogously, Lv et al. indicated that miR-21 promoted

survival and suppressed apoptosis in the human osteosarcoma line MG63¹³. Our findings were partly consistent with the study of Lv et al., suggesting that miR-21 acted as an oncogene of osteosarcoma by controlling tumor cell survival and apoptosis.

Previous studies have demonstrated that multiple genes could serve as target genes of miR-21, including phosphatase and tensin homolog (PTEN), Ras homolog family member B (RhoB), and TIMP metallopeptidase inhibitor 3 (TIMP3)²³⁻²⁵. However, in this study we found that caspase 8 was a target of miR-21, and it was negatively regulated by miR-21. In fact, previous studies have demonstrated that caspase 8 was a downstream gene of miR-21. miR-21 has been found to be endowed with anti-apoptosis properties by activating caspase 3 and caspase 8 fragments in the condition of renal ischemia reperfusion injury²⁶. Moreover, the antiapoptotic function of miR-21 was sufficient for inhibition of caspase 8 activity in a transgenic mouse heart²⁷. Our findings were consistent with these previous investigations and suggested that caspase 8 was a target of miR-21.

The caspase activation mechanism is a major signaling pathway leading to apoptosis²⁸. Caspases are divided into effectors (such as caspases 3, 6, and 7) and initiators (such as caspases 8 and 9)²⁹. The cleaved caspase 8 subsequently initiates apoptosis via proteolytic




Figure 4. Caspase-8 was negatively regulated by miR-21. Cells were transfected with miR-21 mimic, miR-21 inhibitor, or control. Then (A) the mRNA level expression of caspase 8 was measured by qPCR, and (B, C) the protein expressions of caspase 8 and cleaved caspase 8 were measured by Western blot. Cells were transfected with small interfering RNA (siRNA) against caspase 8 and/or the miR-21 inhibitor, and then (D) the mRNA level of caspase 8 and (E, F) the protein expressions of caspase 8 and cleaved caspase 8 were measured. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ when compared to the control.

activation of downstream effector caspases³⁰. Furthermore, it has been demonstrated that caspase 8 plays a vital role in osteosarcoma cell apoptosis^{31–33}. In this study, caspase 8 silencing remarkably decreased the apoptotic cell rate, whereas miR-21 suppression partly recovered the decreased apoptosis. Taken together, we inferred that miR-21-inhibited apoptosis might be via targeting caspase 8.

In conclusion, miR-21 was elevated in osteosarcoma, and overexpression of miR-21 suppressed apoptosis via targeting caspase 8. These findings suggest that miR-21 might be a potential biomarker in the diagnosis of osteosarcoma. Besides, inhibition of miR-21 might be a therapeutic strategy for the treatment of this disease by controlling apoptosis. Nevertheless, further investigation is still needed to explore the deep mechanisms of miR-21 on osteosarcoma.




Figure 5. Overexpression of miR-21 suppressed SAOS-2 cell apoptosis via targeting caspase 8. (A, B) Cells were transfected with siRNA against caspase 8 and/or the miR-21 inhibitor, and then the apoptotic cell rate was determined by flow cytometry. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ when compared to the control.

REFERENCES

- Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007;2:6.
- Powers M, Zhang W, Lopez-Terrada D, Czerniak BA, Lazar AJ. The molecular pathology of sarcomas. Cancer Biomark. 2010;9:475–91.
- Gorlick R, Khanna C. Osteosarcoma. J Bone Miner Res. 2010;25:683–91.
- Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 2007;26:1–18.
- Shi H, Mu WD, Zhang B, Meng T, Zhang ST, Zhou DS. Potential role of S-adenosylmethionine in osteosarcoma development. Onco Targets Ther. 2016;9:3653–9.
- Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, Gonzalez MV, Baldini N, Garcia-Castro J, Rodriguez R. Osteosarcoma: Cells-of-origin, cancer stem cells, and targeted therapies. Stem Cells Int. 2016;2016:3631764.
- Li Y, Deng X, Zeng X, Peng X. The role of mir-148a in cancer. J Cancer 2016;7:1233–41.
- Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004;116:281–97.
- Wang GC, He QY, Tong DK, Wang CF, Liu K, Ding C, Ji F, Zhang H. MiR-367 negatively regulates apoptosis induced by adriamycin in osteosarcoma cells by targeting KLF4. J Bone Oncol. 2016;5:51–6.
- Geng S, Gu L, Ju F, Zhang H, Wang Y, Tang H, Bi Z, Yang C. MicroRNA-224 promotes the sensitivity of osteosarcoma cells to cisplatin by targeting Rac1. J Cell Mol Med. 2016;20:1611–9.
- Lin BC, Huang D, Yu CQ, Mou Y, Liu YH, Zhang DW, Shi FJ. MicroRNA-184 modulates doxorubicin resistance in osteosarcoma cells by targeting BCL2L1. Med Sci Monit. 2016;22:1761–5.
- Wang S, Wan X, Ruan Q. The microRNA-21 in autoimmune diseases. Int J Mol Sci. 2016;17(6).

13. Lv C, Hao Y, Tu G. MicroRNA-21 promotes proliferation, invasion and suppresses apoptosis in human osteosarcoma line MG63 through PTEN/Akt pathway. *Tumour Biol.* 2016;37:9333–42.
14. Ziyang W, Yang L. MicroRNA-21 regulates the sensitivity to cisplatin in a human osteosarcoma cell line. *Ir J Med Sci.* 2016;185:85–91.
15. Li W, Xie P, Ruan WH. Overexpression of lncRNA UCA1 promotes osteosarcoma progression and correlates with poor prognosis. *J Bone Oncol.* 2016;5:80–5.
16. Fu HL, Shao L. Silencing of NUF2 inhibits proliferation of human osteosarcoma Saos-2 cells. *Eur Rev Med Pharmacol Sci.* 2016;20:1071–9.
17. Jo DH, Kim JH, Cho CS, Cho YL, Jun HO, Yu YS, Min JK, Kim JH. STAT3 inhibition suppresses proliferation of retinoblastoma through down-regulation of positive feedback loop of STAT3/miR-17-92 clusters. *Oncotarget* 2014; 5:11513–25.
18. Ju JH, Jang K, Lee KM, Kim M, Kim J, Yi JY, Noh DY, Shin I. CD24 enhances DNA damage-induced apoptosis by modulating NF-kappaB signaling in CD44-expressing breast cancer cells. *Carcinogenesis* 2011;32:1474–83.
19. Zou J, Xu Y. MicroRNA-140 inhibits cell proliferation in gastric cancer cell line HGC-27 by suppressing SOX4. *Med Sci Monit.* 2016;22:2243–52.
20. Zhang N, Su Y, Xu L. Targeting PKCepsilon by miR-143 regulates cell apoptosis in lung cancer. *FEBS Lett.* 2013;587:3661–7.
21. Shi W, Bruce J, Lee M, Yue S, Rowe M, Pintilie M, Kogo R, Bissey PA, Fyles A, Yip KW, Liu FF. MiR-449a promotes breast cancer progression by targeting CRIP2. *Oncotarget* 2016;7:18906–18.
22. Kawano M, Tanaka K, Itonaga I, Ikeda S, Iwasaki T, Tsumura H. microRNA-93 promotes cell proliferation via targeting of PTEN in Osteosarcoma cells. *J Exp Clin Cancer Res.* 2015;34:76.
23. Kuang Y, Nie YJ. Exploration of the regulatory effect of miR-21 on breast cancer cell line proliferation and invasion as well as the downstream target genes. *Asian Pac J Trop Med.* 2016;9:470–3.
24. Connolly EC, Van Doorslaer K, Rogler LE, Rogler CE. Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. *Mol Cancer Res.* 2010;8:691–700.
25. Nagao Y, Hisaoka M, Matsuyama A, Kanemitsu S, Hamada T, Fukuyama T, Nakano R, Uchiyama A, Kawamoto M, Yamaguchi K, Hashimoto H. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma. *Mod Pathol.* 2012;25:112–21.
26. Hu H, Jiang W, Xi X, Zou C, Ye Z. MicroRNA-21 attenuates renal ischemia reperfusion injury via targeting caspase signaling in mice. *Am J Nephrol.* 2014;40:215–23.
27. Sayed D, He M, Hong C, Gao S, Rane S, Yang Z, Abdellatif M. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. *J Biol Chem.* 2010;285:20281–90.
28. Gukovskaya AS, Pandol SJ. Cell death pathways in pancreatitis and pancreatic cancer. *Pancreatology* 2004;4:567–86.
29. Jakubowska K, Guzikowska-Ustymowicz K, Famulski W, Cepowicz D, Jagodzinska D, Pryczynicz A. Reduced expression of caspase-8 and cleaved caspase-3 in pancreatic ductal adenocarcinoma cells. *Oncol Lett.* 2016;11:1879–84.
30. Stiguleto V, Lawlor KE, Vince JE. New insights into the regulation of innate immunity by caspase-8. *Arthritis Res Ther.* 2016;18:4.
31. Ito Y, Pandey P, Sporn MB, Datta R, Kharbanda S, Kufe D. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. *Mol Pharmacol.* 2001;59:1094–9.
32. Seki K, Yoshikawa H, Shiiki K, Hamada Y, Akamatsu N, Tasaka K. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. *Cancer Chemother Pharmacol.* 2000;45:199–206.
33. Yan XB, Yang DS, Gao X, Feng J, Shi ZL, Ye Z. Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132. *Cell Biol Int.* 2007;31:1136–43.